What is the mode of inheritance of thrombophilia (thrombophilia is a condition characterized by hypercoagulability)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

Thrombophilia is primarily inherited through an autosomal dominant pattern, with the most common genetic causes being the Factor V Leiden mutation and the Prothrombin G20210A mutation. The mode of inheritance of thrombophilia is a critical factor in understanding the risk of developing blood clots, particularly in individuals with a family history of the condition. According to the American College of Medical Genetics consensus statement on Factor V Leiden mutation testing 1, the Factor V Leiden mutation is the most common genetic risk factor for venous thrombosis, present in 5% of Caucasian Americans and 20% of idiopathic first venous thrombosis cases.

Key points to consider:

  • The Factor V Leiden mutation and Prothrombin G20210A mutation are the most common inherited thrombophilias, typically inherited in an autosomal dominant pattern 1
  • Individuals with these mutations have an increased risk of developing blood clots, particularly during high-risk situations like surgery, pregnancy, or prolonged immobility 1
  • Genetic testing may be recommended for individuals with a family history of unexplained blood clots, especially at a young age or in unusual locations 1
  • Understanding the genetic risk of thrombophilia can help guide preventive measures, such as anticoagulant medications during high-risk periods 1

It is essential to note that while the evidence suggests an autosomal dominant pattern of inheritance for the most common genetic causes of thrombophilia, the condition can also be influenced by acquired or environmental factors, such as pregnancy, oral contraceptive use, or malignancy 1. Therefore, a comprehensive approach to preventing and managing thrombophilia should consider both genetic and environmental risk factors.

From the FDA Drug Label

Hereditary or acquired deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration. The mode of inheritance of thrombophilia is hereditary, as hereditary deficiencies of protein C or its cofactor, protein S, have been associated with tissue necrosis following warfarin administration 2.

From the Research

Mode of Inheritance of Thrombophilia

The mode of inheritance of thrombophilia is complex and involves both genetic and acquired risk factors.

  • Thrombophilia may have autosomal dominant, autosomal recessive or X-linked inheritance 3.
  • The prothrombin G20210A gene mutation is inherited in an autosomal dominant pattern with variable penetrance 4.
  • Factor V Leiden thrombophilia is also inherited in an autosomal dominant pattern, with heterozygous individuals having an increased risk of thrombosis 5, 6.
  • Deficiencies in natural anticoagulants, such as antithrombin, protein C, and protein S, can also contribute to thrombophilia and may be inherited in an autosomal recessive pattern 5, 7.

Genetic Risk Factors

Several genetic risk factors have been identified as contributing to thrombophilia, including:

  • Factor V Leiden mutation 5, 6, 7
  • Prothrombin G20210A mutation 5, 6, 4, 7
  • Deficiencies in natural anticoagulants (antithrombin, protein C, and protein S) 5, 7
  • Hyperhomocysteinemia 5, 7
  • Elevations in clotting factors (factors VIII and XI) 5

Implications of Genetic Risk Factors

Identification of genetic risk factors can help identify patients at high risk of thrombophilia and guide management and treatment decisions 6, 3, 7.

  • Genetic testing can confirm diagnosis, evaluate recurrence risk, and identify asymptomatic individuals with a known mutation 3.
  • Knowledge of genetic risk factors can also inform the development of personalized treatment plans 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Hereditary thrombophilia.

Acta bio-medica : Atenei Parmensis, 2019

Research

Inherited Thrombophilia.

Journal of pharmacy practice, 2014

Research

An overview of genetic risk factors in thrombophilia.

Srpski arhiv za celokupno lekarstvo, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.